The dvm360® oncology page is a comprehensive resource for clinical news and insights on the latest in veterinary oncology. This page consists of videos, interviews, articles, podcasts, and research on the advancements and developments of therapies for oncology, and more.
November 12th 2024
Canalevia-CA1 is currently the only treatment on the market for treating CID in canine patients.
September 24th 2024
An Interview with Dr. Timothy M. Fan
April 1st 2007Practitioners, says this veterinary oncologist, must be not only clinically competent but also caring and compassionate. "A good veterinarian is like a ball of wax-he or she can be shaped to the different circumstances and needs of the patient and pet owner."
Pfizer donates $1.1 million to canine tumor bank
February 27th 2007New York - 2/27/07 - Pfizer Animal Health donated $1.1 million to the Morris Animal Foundation (MAF) to establish a national canine tumor biospecimen bank. The bank is expected to be valuable in treating dogs and may provide insights into human cancer. Funds for the tumor bank are restricted to the Canine Comparative Oncology and Geriatrics Consortium (CCOGC), a group of veterinary and medical researchers who have determined that a well-described repository of canine-tumor tissues is an essential resource for progress in new cancer therapies.
Deciphering the histiocytic code
December 1st 2006Many clinicians cringe when they see the word histiocytic on a diagnostic report. The nomenclature of histiocytic diseases can be difficult to understand, leading to confusion in regards to diagnostic and therapeutic options. To further compound the confusion, it can be easy to misdiagnose these diseases with only routine histopathology. This article is designed to provide a better understanding of the histiocytic diseases, as well as to provide information regarding the diagnosis and clinical presentation of these diseases and available treatment options.
Practical Matters: Difficulties in diagnosing transitional cell carcinoma
October 1st 2006Diagnosing transitional cell carcinoma can be a difficult clinical challenge. Clinical signs (pollakiuria, dysuria, stranguria, and hematuria) are nonspecific, and differential diagnoses include granulomatous cystitis, other neoplastic diseases (lymphoma, rhabdomyosarcoma), a persistent or recurrent urinary tract infection, and urinary calculi-the latter two of which may occur concurrently with transitional cell carcinoma.
Canine and feline oral tumors: Earlier is better
July 1st 2006Oral tumors are the fourth most common cancer in dogs and represent 6 percent of all canine cancers. The most common malignant tumors in dogs are melanoma, fibrosarcoma, SCC and osteosarcoma. Benign tumors include the epulides (ossifying, fibromatous and acanthomatous) and other odontogenic tumors. In cats, oral tumors make up 3 percent of all feline cancers. SCC is the most common malignant tumor followed by fibrosarcoma. Benign oral tumors are much less common in cats.
Research Update: The utility of ultrasonography to detect brachial plexus tumors in dogs
May 1st 2006In this retrospective study from a university teaching hospital, five dogs with progressive, unilateral forelimb lameness and neurologic deficits having undergone ultrasonographic evaluation of the brachial plexus region were described.
Research Update: How effective is surgical excision of feline cutaneous hemangiosarcomas?
September 1st 2005In this retrospective study from the Animal Medical Center in New York City, the medical records of 18 cats with feline cutaneous hemangiosarcoma were reviewed, and the cats' clinical features and responses to surgery were described.
Current treatment options for dogs with appendicular osteosarcoma
April 1st 2005Although amputation has traditionally been used to palliatively manage affected dogs, treatment modalities including limb salvage, radiation therapy, and chemotherapy are evolving. This overview of emerging therapies will help you educate owners about treatment options for dogs with appendicular osteosarcoma.